Wiener klinisches Magazin

, Volume 13, Issue 2, pp 32–43

Ein „gefährliches Duo“

Diabetes-spezifische Aspekte der Koronaren Herzkrankheit
  • Maria M. Wanitschek
  • Otmar Pachinger
  • Hannes F. Alber
Stoffwechsel
  • 28 Downloads
Diabetes mellitus (DM) und die koronare Herzkrankheit (KHK) sind ein „gefährliches Duo“ mit hoher Mortalität und Morbidität. Angesichts der steigenden Prävalenz des DM Typ 2 generell (1, 2) und im Alter (3) sowie der immer älter werdenden Bevölkerung wird die Zahl der zu behandelnden Patienten mit beiden Erkrankungen zukünftig noch weiter steigen. Dieser Artikel zielt daher auf eine kritische Betrachtung der Kombination aus DM und KHK ab. Im Detail sollen folgende Aspekte diskutiert werden:
  1. epidemiologische Aspekt

     
  2. pathomechanistische Aspekte

     
  3. diagnostische Aspekte

     
  4. therapeutische Aspekte

     

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    King H, Aubert RE and Herman WH (1998). Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 21: 1414–31 CrossRefPubMedGoogle Scholar
  2. 2.
    Wild S, Roglic G, Green A, Sicree R and King H (2004). Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27: 1047–53 CrossRefPubMedGoogle Scholar
  3. 3.
    Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care 2003; 26:61–9Google Scholar
  4. 4.
    Ryden L, Standl E and Bartnik M et al (2007). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28: 88–136 CrossRefPubMedGoogle Scholar
  5. 5.
    Gu K, Cowie CC and Harris MI (1999). Diabetes and decline in heart disease mortality in US adults. Jama 281: 1291–7 CrossRefPubMedGoogle Scholar
  6. 6.
    Fox CS, Coady S and Sorlie PD et al (2004). Trends in cardiovascular complications of diabetes. Jama 292: 2495–9 CrossRefPubMedGoogle Scholar
  7. 7.
    Juutilainen A, Lehto S, Ronnemaa T, Pyorala K and Laakso M (2005). Type 2 diabetes as a „coronary heart disease equivalent“: an 18-year prospective population-based study in Finnish subjects. Diabetes Care 28: 2901–7 CrossRefPubMedGoogle Scholar
  8. 8.
    Booth GL, Kapral MK, Fung K and Tu JV (2006). Relation between age and cardiovascular disease in men and women with diabetes compared with nondiabetic people: a population-based retrospective cohort study. Lancet 368: 29–36 CrossRefPubMedGoogle Scholar
  9. 9.
    Sambola A, Osende J and Hathcock J et al (2003). Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation 107: 973–7 CrossRefPubMedGoogle Scholar
  10. 10.
    Mazzone T, Chait A and Plutzky J (2008). Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet 371: 1800–9 CrossRefPubMedGoogle Scholar
  11. 11.
    Creager MA, Luscher TF, Cosentino F and Beckman JA (2003). Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 108: 1527–32 CrossRefPubMedGoogle Scholar
  12. 12.
    Luscher TF, Creager MA, Beckman JA and Cosentino F (2003). Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part II. Circulation 108: 1655–61 CrossRefPubMedGoogle Scholar
  13. 13.
    Moreno PR, Murcia AM and Palacios IF et al (2000). Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 102: 2180–4 PubMedGoogle Scholar
  14. 14.
    Goldberg IJ (2001). Clinical review 124: Diabetic dyslipidemia: causes and consequences. J Clin Endocrinol Metab 86: 965–71 CrossRefPubMedGoogle Scholar
  15. 15.
    Mooradian AD, Haas MJ and Wong NC (2004). Transcriptional control of apolipoprotein A-I gene expression in diabetes. Diabetes 53: 513–20 CrossRefPubMedGoogle Scholar
  16. 16.
    Gowri MS, Van der Westhuyzen DR, Bridges SR and Anderson JW (1999). Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may Be due to the abnormal composition of HDL. Arterioscler Thromb Vasc Biol 19: 2226–33 PubMedGoogle Scholar
  17. 17.
    Chahil TJ and Ginsberg HN (2006). Diabetic dyslipidemia. Endocrinol Metab Clin North Am 35: 491–510 vii–viii CrossRefPubMedGoogle Scholar
  18. 18.
    Ledru F, Ducimetiere P and Battaglia S et al (2001). New diagnostic criteria for diabetes and coronary artery disease: insights from an angiographic study. J Am Coll Cardiol 37: 1543–50 CrossRefPubMedGoogle Scholar
  19. 19.
    Abaci A, Oguzhan A and Kahraman S et al (1999). Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 99: 2239–42 PubMedGoogle Scholar
  20. 20.
    Marx N and Blessing E (2007). [Diabetes mellitus and coronary artery disease. Update on diagnosis and drug therapy]. Dtsch Med Wochenschr 132: 1034–8 CrossRefPubMedGoogle Scholar
  21. 21.
    Consensus development conference on the diagnosis of coronary heart disease in people with diabetes: 10–11 February 1998, Miami, Florida. American Diabetes Association. Diabetes Care 1998; 21:1551–9Google Scholar
  22. 22.
    Bax JJ, Young LH, Frye RL, Bonow RO, Steinberg HO and Barrett EJ (2007). Screening for coronary artery disease in patients with diabetes. Diabetes Care 30: 2729–36 CrossRefPubMedGoogle Scholar
  23. 23.
    Scognamiglio R, Negut C, Ramondo A, Tiengo A and Avogaro A (2006). Detection of coronary artery disease in asymptomatic patients with type 2 diabetes mellitus. J Am Coll Cardiol 47: 65–71 CrossRefPubMedGoogle Scholar
  24. 24.
    Standards of medical care in diabetes. Diabetes Care 2005; 28 Suppl 1:S4–S36Google Scholar
  25. 25.
    O’Rourke RA, Brundage BH and Froelicher VF et al (2000). American College of Cardiology/American Heart Association Expert Consensus Document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. J Am Coll Cardiol 36: 326–40 CrossRefPubMedGoogle Scholar
  26. 26.
    Anand DV, Lim E and Hopkins D et al (2006). Risk stratification in uncomplicated type 2 diabetes: prospective evaluation of the combined use of coronary artery calcium imaging and selective myocardial perfusion scintigraphy. Eur Heart J 27: 713–21 CrossRefPubMedGoogle Scholar
  27. 27.
    Anand DV, Lim E, Lahiri A and Bax JJ (2006). The role of non-invasive imaging in the risk stratification of asymptomatic diabetic subjects. Eur Heart J 27: 905–12 CrossRefPubMedGoogle Scholar
  28. 28.
    Hendel RC, Patel MR and Kramer CM et al (2006). ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/ SIR 2006 appropriateness criteria for cardiac computed tomography and cardiac magnetic resonance imaging: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American College of Radiology, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, North American Society for Cardiac Imaging, Society for Cardiovascular Angiography and Interventions, and Society of Interventional Radiology. J Am Coll Cardiol 48: 1475–97 CrossRefPubMedGoogle Scholar
  29. 29.
    Bassand JP, Hamm CW and Ardissino D et al (2007). Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syn-dromes. Eur Heart J 28: 1598–660 CrossRefPubMedGoogle Scholar
  30. 30.
    Van de Werf F, Bax J and Betriu A et al (2008). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 29: 2909–45 CrossRefPubMedGoogle Scholar
  31. 31.
    Hansson L, Zanchetti A and Carruthers SG et al (1998). Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351: 1755–62 Google Scholar
  32. 32.
    Califf RM and Granger CB (1998). Hypertension and diabetes and the Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET). More ammunition against surrogate end points. Diabetes Care 21: 655–7 CrossRefPubMedGoogle Scholar
  33. 33.
    Tatti P, Pahor M and Byington RP et al (1998). Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 21: 597–603 CrossRefPubMedGoogle Scholar
  34. 34.
    Hansson L, Lindholm LH and Niskanen L et al (1999). Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353: 611–6 CrossRefPubMedGoogle Scholar
  35. 35.
    Niskanen L, Hedner T, Hansson L, Lanke J and Niklason A (2001). Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care 24: 2091–6 CrossRefPubMedGoogle Scholar
  36. 36.
    Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Jama 2002; 288:2981–97Google Scholar
  37. 37.
    Turner RC, Millns H and Neil HA et al (1998). Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). Bmj 316: 823–8 PubMedGoogle Scholar
  38. 38.
    Grundy SM, Cleeman JI and Merz CN et al (2004). Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110: 227–39 CrossRefPubMedGoogle Scholar
  39. 39.
    Shepherd J, Barter P and Carmena R et al (2006). Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 29: 1220–6 CrossRefPubMedGoogle Scholar
  40. 40.
    De Berardis G, Sacco M and Strippoli GF et al (2009). Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. Bmj 339: b4531 CrossRefPubMedGoogle Scholar
  41. 41.
    Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH and Pedersen O (2003). Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348: 383–93 CrossRefPubMedGoogle Scholar
  42. 42.
    Gaede P, Lund-Andersen H, Parving HH and Pedersen O (2008). Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358: 580–91 CrossRefPubMedGoogle Scholar
  43. 43.
    Frye RL, August P and Brooks MM et al (2009). A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 360: 2503–15 CrossRefPubMedGoogle Scholar
  44. 44.
    Hachamovitch R, Hayes SW, Friedman JD, Cohen I and Berman DS (2003). Comparison of the shortterm survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 107: 2900–7 CrossRefPubMedGoogle Scholar
  45. 45.
    Shaw LJ, Berman DS and Maron DJ et al (2008). Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 117: 1283–91 CrossRefPubMedGoogle Scholar
  46. 46.
    Daemen J, Boersma E and Flather M et al (2008). Longterm safety and efficacy of percutaneous coronary intervention with stenting and coronary artery bypass surgery for multivessel coronary artery disease: a meta-analysis with 5-year patient- level data from the ARTS, ERACI-II, MASSII, and SoS trials. Circulation 118: 1146–54 CrossRefPubMedGoogle Scholar
  47. 47.
    Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med 1996; 335:217–25Google Scholar
  48. 48.
    Serruys PW, Morice MC and Kappetein AP et al (2009). Percutaneous coronary intervention versus coronary- artery bypass grafting for severe coronary artery disease. N Engl J Med 360: 961–72 CrossRefPubMedGoogle Scholar
  49. 49.
    Duckworth W, Abraira C and Moritz T et al (2009). Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360: 129–39 CrossRefPubMedGoogle Scholar
  50. 50.
    Patel A, MacMahon S and Chalmers J et al (2008). Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358: 2560–72 CrossRefPubMedGoogle Scholar
  51. 51.
    Gerstein HC, Miller ME and Byington RP et al (2008). Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358: 2545–59 CrossRefPubMedGoogle Scholar
  52. 52.
    Skyler JS, Bergenstal R and Bonow RO et al (2009). Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 119: 351–7 CrossRefPubMedGoogle Scholar
  53. 53.
    Dluhy RG and McMahon GT (2008). Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 358: 2630–3 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Wien 2010

Authors and Affiliations

  • Maria M. Wanitschek
    • 1
  • Otmar Pachinger
    • 1
  • Hannes F. Alber
    • 1
  1. 1.Universitätsklinik für Innere Medizin III, Kardiologie Medizinische Universität InnsbruckInnsbruckAustria

Personalised recommendations